ERBB2 and breast cancer: Furthermore, since RIPK2 is a robust driver of inflammation in IBC tissues, it may be a good biomarker to monitor the effectiveness of neoadjuvant chemotherapy and be an interesting additional therapeutic option in HER2 negative breast cancer and as another co-therapy for patients that display HER2 overexpression.